Figure S4 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S1 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S5 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S3 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Figure S2 from Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer
2026-06-17
Abstract CT166: A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC)
Cancer Research · 2026-04-17
Abstract LB331: First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results
Cancer Research · 2026-04-17
Abstract LB010: First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2
Cancer Research · 2026-04-17
Abstract 1182: A unified clinical and molecular framework to standardize chromosomal instability assessment in gastric, GEJ, and esophageal cancer (GEC).
Cancer Research · 2026-04-03
Abstract 6563: Immune and clinical determinants of response to immune checkpoint blockade (ICB) rechallenge after perioperative chemoImmunotherapy in gastroesophageal cancer
Cancer Research · 2026-04-03
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
JCO Precision Oncology · 2026-04-01
Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer
Journal of Nuclear Medicine · 2026-02-26
Making sense of <scp>TILs</scp> : recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma
Histopathology · 2026-02-05
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
Journal of Clinical Oncology · 2026-01-10 · 1 citations
Survival outcomes for phase II study of durvalumab (D) and tremelimumab (T) plus PET-directed chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma (EA).
Journal of Clinical Oncology · 2026-01-10
AMIGO: A phase 2 trial of amivantamab in <i>EGFR</i> or <i>MET-</i> amplified gastroesophageal adenocarcinoma (GEA).
Journal of Clinical Oncology · 2026-01-10 · 1 citations
GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
Journal of Clinical Oncology · 2026-01-10
First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.
Journal of Clinical Oncology · 2026-01-10 · 1 citations
CLARITY-Gastric 01: A randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
Journal of Clinical Oncology · 2026-01-10
Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Journal of Clinical Oncology · 2026-01-10 · 1 citations